3.750USD-1.32%Mkt Cap: 231.11M USDP/E: —Last update: 2026-05-26
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibod…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap231.11M USD
Enterprise Value115.44M USD
Revenue (TTM)36.49M USD
Gross Profit-88.86M USD
Net Income (TTM)-119.72M USD
Revenue/Share0.6190 USD
Last Price3.750 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees141
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS92915B1061
Valuation
P/E (Trailing)—
P/E (Forward)-2.37
PEG—
EV/EBITDA-0.96
EV/Revenue3.16
P/S6.09
P/B1.11
EPS (TTM)-1.98
EPS (Forward)-1.55
52W Range
2.65038% of range5.550
52W High5.550 USD
52W Low2.650 USD
Profitability
Gross Margin-243.48%
Oper. Margin-1167.37%
EBITDA Margin0.00%
Profit Margin-296.53%
ROE-61.06%
ROA-47.46%
Growth
Revenue Growth-59.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-132.47M USD
CapEx (TTM)2.60M USD
FCF Margin-221.49%
FCF Yield-34.97%
Net Debt-106.91M USD
Net Debt/EBITDA0.89
Balance Sheet
Debt/Equity0.19
Current Ratio8.42
Quick Ratio8.20
Book Value/Sh3.321 USD
Cash/Share2.342 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)14.89 USD
Target Range8.000 USD – 25.00 USD
# Analysts9
Ownership
Shares Out.60.42M
Float44.22M
Insiders15.14%
Institutions56.37%
Short Interest
Short Ratio6.8d
Short % Float7.12%
Short % Out.6.06%
Shares Short3.66M
Short (prev mo.)3.29M
Technical
SMA 503.951 (-5.1%)
SMA 2004.072 (-7.9%)
Beta1.26
S&P 52W Chg28.31%
Avg Vol (30d)541.61K
Avg Vol (10d)690.57K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—